News

Extend Biosciences was awarded a Phase II SBIR grant from the National Cancer Institute to fund efficacy and IND-enabling studies for a long-acting ghrelin molecule for cancer cachexia.

Extend Biosciences’ third patent has been awarded by the USPTO. The patent, titled “Insulin Vitamin D Conjugates” issued April 11, 2017 (US 9,616,109). 

In a Shark Tank-style event sponsored by Women In Bio, Extend Biosciences founder Laura Hales, Ph.D. won first prize (an All-Clad Lobster Pot!) in the pitch competition in front of >100 audience members and 4 investors.  The event, held at LabCentral, featured 6 companies pitching from life sciences and healthcare, and was moderated by Marian Nakada of JJDC.

Extend Biosciences was awarded a Phase I SBIR grant from the National Institute of Allergy and Infectious Disease to work on a program for acute radiation syndrome.

Extend Biosciences has completed their 3-year maximum stay at LabCentral, and said goodbye to fellow residents and staff at a happy hour in the playroom. The party was co-hosted with Advirna, who was also moving on. On February 1, Extend Biosciences will move to LabShares, a shared laboratory facility in Newton.

See the post on Twitter->

Laura Hales, Cofounder of Extend Biosciences, spoke about her journey in biotech and entrepreneurship, and path to successfully obtaining SBIR funding on a panel on October 5. The panel was moderated by Esther Morales, Executive Director of the National Women’s Business Council, and included Barbara Fox, PhD, Marian Nakada, PhD, and Joanne Kamens, PhD. The title of the panel was “It’s All of Our Business: Succeeding as a Woman in STEM” and was part of the pre-conference to the 2016 SBIR New England Regional Summit at MIT.

Extend Biosciences was featured in the NSF Innovation Zone at the BIO International Convention 2016 in San Francisco, CA.  The company received complimentary passes to the Convention, and the technology was showcased at the company’s kiosk in the Innovation Zone with a poster and a pitch presentation by CEO Tarik Soliman.

Read the press release here->

Extend Biosciences’ second patent has been awarded by the USPTO. The patent, titled “Carriers for Improved Drug Delivery” issued March 22, 2016 (US 9,289,507). The patent includes broad claims for the use of vitamin D to improve the pharmacokinetic properties of therapeutic entities.

Extend Biosciences’ CEO Tarik Soliman gave a talk at the Boulder Peptide Symposium’s Peptide Showcase East conference held at the Microsoft NERD Center in Cambridge, MA. The talk was titled “Harnessing the biology of vitamin D to enable sustained delivery of peptides and proteins.”

See the Proceedings Abstract here ->

Extend Biosciences’ first patent has been awarded. The patent, titled “Vitamin D-ghrelin Conjugates” issued Nov. 3, 2015 (US 9,173,940).